

**REMARKS**

Claims 1 to 12 are pending in the application. Claims 1 to 12 are subject to restriction.

***Election/Restrictions***

Regarding item 1 of the Office Action, Applicants hereby elect the invention of Group II, Claims 1, 2, and 4 to 12 in part, drawn to a naphthyridine compound (i.e., Y is C(=O), CH<sub>2</sub>, or C(H)(R<sup>7</sup>), W<sup>1</sup> is C(H)R<sup>5</sup> or CR<sup>5</sup>, one of W<sup>2</sup>, W<sup>3</sup>, and W<sup>4</sup> is N and the other two of W<sup>2</sup>, W<sup>3</sup>, and W<sup>4</sup> are CR<sup>5</sup>, classified in class 546, subclass 122, the composition, and method of uses thereof.

Applicants believe the above description of the invention of Group II is in accordance with the invention of Group II. Applicants note, however, that the description of the invention of Group II in the Office Action was unclear with respect to W<sup>2</sup>, W<sup>3</sup>, and W<sup>4</sup>, as W<sup>2</sup>, W<sup>3</sup>, and W<sup>4</sup> cannot be "NR<sup>5</sup>" as alleged by the Examiner. Accordingly, Applicants make their election with traverse until the discrepancy is cleared up.

Regarding item 2 of the Office Action, Applicants elect the species of the invention of Group II that is recited in Claim 8, on page 128, at lines 1 and 2, namely 4-[1-oxo-7-(3-[1,2,3]triazol-1-ylprop-1-ynyl)-1H-6-azaisoquinolin-2-ylmethyl]benzoic acid. The elected species may also be named, 4-[1-oxo-7-(3-[1,2,3]triazol-1-yl-prop-1-ynyl)-1H-[2,6]naphthyridin-2-ylmethyl]-benzoic acid.

***Supplemental Information Disclosure Statement***

Applicants make available to the Patent and Trademark Office a Supplemental Information Disclosure Statement on forms PTO/SB/08A and/or PTO/SB/08B and a copy of the art cited thereon. Applicants respectfully request that the Examiner consider carefully the complete text of the cited reference(s) in connection with the continued examination of the above-identified application in accord with 37 CFR §1.104(a).

It is respectfully requested that all cited reference(s) considered by the Examiner be listed in the "References Cited" portion of any patent issuing from the instant application (MPEP § 1302.12).

***Conclusion***

Applicants request consideration and allowance of the elected subject matter of Claims 1, 2, and 4 to 12 in part.

The undersigned can be contacted at the below-recited telephone number.

Respectfully submitted,

Date: October 13, 2004

Claude F. Purchase Jr.

Claude F. Purchase, Jr.

Reg. No. 47,871

Pfizer Inc.

2800 Plymouth Road

Ann Arbor, MI 48105

Tel. (734) 622-1692

Fax (734) 622-1553